The symposium titled“multi-center studies of applications of early screening Program in Nasopharyngeal Carcinoma ” took place in city of Changsha on 27th August, 2016. China Health Promotion Foundation and Central South University Xiangya Hospital co-hosted this symposium. More than 60 KOLs from dozens of clinical departments of medical centers and hospitals attended this event.
Recently, the CFDA approved Rta Nasopharyngeal carcinoma biomarker had demonstrated encouraging results in clinical uses. The Rta kit is simple and easy to operate. It can be used in clinical diagnosis of NPC, as well as screening of NPC in healthcare management institutions. Rta is officially selected for this multi-center studies of applications of early screening program in Nasopharyngeal Carcinoma. The China Health Promotion Foundation believed that under the guidance of the scientific committee, this project will achieve satisfactory results in early detection and screening of NPC.
This multi-center studies of applications of early screening Program in Nasopharyngeal Carcinoma will be promoted nationwide through China Health Promotion Foundation. Tarcine BioMed will help build a Rta testing collaboration platform and establish common understanding, SOPs, industry standards and a health management pathway for Rta-IgG in physical examination practices. As always, Tarcine is dedicated to early detection and intervention of NPC.